Western tradition · NAD+ precursor · Longevity supplement

NMN (Nicotinamide Mononucleotide) β-烟酰胺单核苷酸

The headline NAD+ booster of the longevity world — human trials show it raises blood NAD+ and may support physical function.

32ClinicalTrials.gov matched
19PubMed RCT records
11Meta-analysis records
31+PubMed records
Nicotinamide mononucleotideKey active compound

Data definition. Matched records include all indexed medical endpoints for this intervention — not only longevity. Longevity-relevant records are screened separately and cited in the evidence summary below. Counts are matched-record volumes, not de-duplicated trials and not efficacy claims.

Origin & tradition

NMN is not a traditional remedy but a modern molecule at the center of the NAD+ longevity field studied at Harvard and Washington University. NAD+, the coenzyme it feeds, declines with age.

Why longevity buyers care

Key active: Nicotinamide mononucleotide (NAD+ precursor).

NMN is a direct precursor to NAD+, the coenzyme that fuels mitochondrial energy and sirtuin activity and declines with age. A 2022 randomized, placebo-controlled trial in healthy middle-aged adults found dose-dependent increases in blood NAD+ and improved six-minute walking distance.

Effect summary

Studied health outcomes

Editorial summary — This table is curated by hand from published research consensus, not automatically calculated from our trial database. Grades reflect our interpretation of the literature. Treat as a starting point, not a definitive verdict. See the Evidence panel below for the underlying trial and paper counts sourced directly from ClinicalTrials.gov and PubMed.
Health outcomeEffectMagnitudeGrade
NAD+ blood levelsIncreasesStrongB
Physical endurance / VO2 maxIncreasesMinorC
Insulin sensitivityIncreasesMinorC
DNA repair markersIncreasesMinorC
Skin hydration & elasticityIncreasesMinorC
Blood pressureNo changeNegligibleD

Grade: A = robust RCTs · B = several RCTs / meta-analysis · C = limited or mixed RCTs · D = observational or early data

Dosage guidance

How NMN (Nicotinamide Mononucleotide) is typically used

Typical dose
250–500 mg/day
Form
capsule or sublingual powder
Timing
morning, with or without food

Higher doses up to 1,500 mg/day studied in some trials; start low. Sublingual may improve absorption.

Informational only — not a prescription or personalised medical advice. Consult a qualified clinician before starting any supplement or medication.

Evidence summary

What the research actually says

79Evidence confidence
Human RCT evidence19 randomized controlled trials · 11 meta-analyses / systematic reviews

Human RCTs on NAD+ levels & physical function; long-term longevity outcomes still open

NMN is a direct precursor to NAD+, the coenzyme that fuels mitochondrial energy and sirtuin activity and declines with age. A 2022 randomized, placebo-controlled trial in healthy middle-aged adults found dose-dependent increases in blood NAD+ and improved six-minute walking distance.

32registered clinical trials reference this intervention
2selected from 31+ PubMed papers (longevity / aging angle)
Key active: Nicotinamide mononucleotide (NAD+ precursor).

According to PubMed and ClinicalTrials.gov: trial counts from ClinicalTrials.gov, peer-reviewed literature from PubMed. Counts auto-refresh weekly; last checked 2026-07-19. They include trials across many endpoints, not only longevity.

Informational only — not medical advice, a treatment claim, or a substitute for a qualified clinician. Evidence strength varies; we show mixed and null results on purpose.

Compare the evidence

Related ingredients

Suppliers

No NMN (Nicotinamide Mononucleotide) suppliers listed yet

Tell us what you need and we will source suppliers for you.

Request sourcing help